AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04314986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 4: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days
Study NCT01340807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specialized Functional Prosthetic Training
Description: Each subject receives specialized functional prosthetic training
Study NCT02461407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib p.o. qd
Study NCT02461407 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study NCT03951701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the supportive care
Description: Evaluation of interest of a systematic screening for oncological supportive care needs
Study NCT04293601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interventional nursing care
Description: The infants enrolled will receive different intervention according to a defined risk factor level:~Low:~* NCPAP duration \< 48 hours (h)~* Gestational Age (GA) > 32 weeks (wks)~* Current weight > 1500 g~Interventions:~* alternating mask or nasal prongs once per shift~* skin assessment (excoriation, erythema or skin breakdown) once per shift~Medium:~* NCPAP duration from 48 to 72 h~* GA from 32 to 28 wks~* Current weight from 1500 to 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) twice per shift~* repositioning of device once per shift~High:~* NCPAP duration > 72 h~* GA \< 28 wks~* Current weight \< 1000 g~Interventions:~* alternating mask or nasal prongs twice per shift~* skin assessment (excoriation, erythema or skin breakdown) every 3 h per shift~* repositioning of device every 3 h per shift
Study NCT04293601 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard nursing care
Description: * Use of hydrocolloid as nasal barrier dressing~* Appropriate size of headbands, indicated by production company~* Appropriate size of mask or binasal prongs, indicated by production company~* Frequently assess skin integrity, every 4 hours~* Replace hydrocolloid if it's dirty or displaced~* Humidity and heat gases
Study NCT00912756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: 200 mg/day BID
Study NCT00912756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol
Description: 200 mg/day BID
Study NCT01587807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1995057
Description: inhaled dose (volume based on cohort)
Study NCT00893880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% gaseous Nitric Oxide blended in Oxygen
Description: 1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
Study NCT04314986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cohort 4: AR882 or placebo
Description: AR882 or matching placebo administered once daily for 10 days
Study NCT00947271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD 1
Description: The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases \[STDs\]) and improve health
Study NCT00947271 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DVD 2
Description: The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health
Study NCT01587807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bronchoalveolar lavage
Description: BAL
Study NCT01587807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPS
Description: 50 μg
Study NCT01587807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
Study NCT04112966 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 14 sessions of manual lymphatic drainage technique
Description: Early manual lymph drainage including 14 sessions of manual lymphatic drainage technique in the three months following surgery and health education for lymphedema prevention including verbal instructions and written materials.
Study NCT04112966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the health education
Description: The health education for lymphedema prevention.
Study NCT04112966 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: the health education
Description: The health education for lymphedema prevention.
Study NCT04064749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messages
Description: The brief intervention includes providing feedback on the individual's gambling score; providing an educational fact about the relationship between problem gambling and financial well-being; talking with the individual about the 'pros' and 'cons' of gambling with suggested strategies that could potentially reduce their gambling behaviors; and concluding with an action oriented closing question. Participants in the intervention group will also receive up to five text messages a week for one month.
Study NCT01006031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a and Ribavirin
Description: Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.~Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels.
Study NCT03353025 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transsphenoidal surgery treatment
Description: transsphenoidal surgery treatment
Study NCT01864343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMCOOLS flex pad; Philips Innercool RTx
Description: Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
Study NCT02741635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New Nasal Pillows Mask
Description: Nasal Pillows mask for the treatment of obstructive sleep apnea (OSA)
Study NCT02289638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubrite
Description: Video-Laryngoscopy
Study NCT02289638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIL
Description: Direct-Laryngoscopy
Study NCT02085018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Drug
Study NCT02085018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo
Study NCT01633541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101
Description: Patients will receive AT-101 40 mg orally two times a day.
Study NCT01633541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (Taxotere) 75 mg/m2
Study NCT01633541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2
Study NCT01633541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 100 mg/m2
Study NCT01633541 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
Study NCT01633541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
Study NCT03015636 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjusted CBT-i for ADHD
Description: This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
Study NCT03353025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dopamine agonist treatment
Description: Minimum effective dose of dopamine agonist，bromocriptine，treat prolactinona
Study NCT04065997 — intervention group
Intervention type: DEVICE
Intervention: HeartWare Ventricular Assist Device
Description: The HVAD is an implantable centrifugal rotary blood pump that is implanted in the pericardial space and is designed to provide up to 10 L/min of blood flow from the left ventricular to the aorta. The HVAD System is comprised of three major components: the HVAD (pump) with inflow and outflow conduits, a Controller (microprocessor unit that controls the operation of the HVAD), and power sources (AC and DC power adapters that provide power to the Controller and implanted HVAD).
Study NCT03015636 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
Study NCT04708093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole body vibration training
Description: Oscillating platform
Study NCT01214005 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: smoking abstinence
Description: 3 days of biologically-confirmed smoking abstinence
Study NCT01214005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking abstinence
Description: 3 days of biologically-confirmed smoking abstinence
Study NCT04394065 — intervention group
Intervention type: DEVICE
Intervention: ultrasensitive positron emission tomography
Description: A 194-cm-long total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER)
Study NCT02552134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Study NCT02552134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: recommendation to be active
Study NCT03797846 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined glaucoma surgery
Description: combined procedure with trabeculectomy and cataract removal
Study NCT01113125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethason-17-valerate and fusidic acid
Description: 0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
Study NCT03309423 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: venous to arterial conversion (v-TAC)
Description: Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
Study NCT02976935 — intervention group
Intervention type: OTHER
Intervention: hyperpolarised 129 Xenon
Description: Hyperpolarised 129 Xe to assess lung function
Study NCT00746616 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durom Hip Resurfacing System
Description: Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
Study NCT02151188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bread, Soy milk and cow milk
Description: The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
Study NCT02151188 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bread, Soy milk and cow milk
Description: The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
Study NCT02151188 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)
Study NCT02151188 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)
Study NCT00296777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 8 weeks: up to 40 mg/day
Study NCT00296777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: 8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
Study NCT00296777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: 8 weeks: up to 300mg/day~\*if patient does not have contraindication.
Study NCT01113125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fusidic Acid
Description: 0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
Study NCT01710007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1PC002
Description: Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
Study NCT03976388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clinical Virtual Simulator
Description: Interactive medical case delivered using touch-sensitive screens in small group sessions.
Study NCT01710007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor
Description: Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
Study NCT03938454 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizanlizumab
Description: Crizanlizumab is a concentrate for solution for infusion, i.v. use. Supplied in single use 10 mL vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab
Study NCT03976388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Small-Group Discussion
Description: Small group discussion led by a physician.
Study NCT01100320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reformulated OXY (oxycodone HCl)
Description: Reformulated OXY 40-mg tablet x 1 dose taken with food
Study NCT03890380 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magneto Wire
Description: Patients will be treated with Magneto Wire
Study NCT01100320 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Original OxyContin® (OXY) (oxycodone HCl)
Description: Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
Study NCT03561272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart Phone Application
Description: Oral medication adherence phone application.
Study NCT03561272 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smart Phone Application
Description: Oral medication adherence phone application.
Study NCT03561272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POD
Description: Pill dispensing system that dispenses the medication, controls dispensed dosage, and confirms dispensing to patient through wireless communication back to the control center.
Study NCT05429749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferinject
Description: Intravenous ferinject 1000mg is administered between the admission day and the surgery day.
Study NCT01627613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP301
Description: AP301 25 mg powder for reconstitution for solution for inhalation~Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days.
Study NCT01627613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
Study NCT05429749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Normal saline 250ml is administered between the admission day and the surgery day.
Study NCT04005261 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: C-peptide concentrations
Description: The patients will be grouped by their C-peptide concentrations
Study NCT02579967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppression Only Conditioning -Closed with amendment L
Description: Pentostatin 4 mg/m2/day IV on days -9 and -5, cyclophosphamide 5 mg/kg orally daily on days -9 through -2 (Closed with amendment L)
Study NCT02579967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced Intensity Conditioning
Description: pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 3 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
Study NCT02579967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myeloablative Conditioning-Closed with amendment L
Description: Pentostatin 4 mg/m2/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2. (Closed with amendment L)
Study NCT02579967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through 0, +18, +25, or +35 depending on treatment arm and cohort.
Study NCT02579967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allo BMT
Description: Allogeneic blood or marrow transplantation
Study NCT00500188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate (Gleevec)
Description: 300 mg orally twice daily
Study NCT03215602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEMEX and education + strength training
Description: Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
Study NCT03215602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NEMEX and education
Description: Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
Study NCT01798056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK 1437173A
Description: 2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
Study NCT01798056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
Study NCT04591327 — intervention group
Intervention type: PROCEDURE
Intervention: The Effect of General Anesthesia and Spinal Anesthesia on Postoperative Atelectasis by Lung Ultrasonography in Cesarean Sections
Description: Preoperative lung ultrasound will be performed on all patients and baseline values will be recorded. The sensory block level under T10 of the patients who underwent spinal anesthesia in the postoperative period lung ultrasonography will be done after regression. In the postoperative period, lung ultrasonography will be performed in patients undergoing spinal anesthesia when the sensory block level is below T10. In the general anesthesia group, when the neuromuscular block is completely reversed and the Aldrete score is> 9, lung ultrasonography will be performed. The degree of atelectasis will be determined according to the modified LUS score.
Study NCT02510131 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises
Description: To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
Study NCT02510131 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
Study NCT02049931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No brace treatment
Description: Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
Study NCT02049931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rigid brace
Description: In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
Study NCT02049931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soft brace
Description: In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.